Literature DB >> 30654239

Isatin derivatives and their anti-bacterial activities.

Hua Guo1.   

Abstract

Bacterial infections are account for the majority of hospital-acquired and community-acquired infections. The emergency and widespread of drug-resistant pathogens has further worsened the situation. In recent years, various isatin derivatives have been screened for their anti-bacterial activities, and some of them demonstrated promising in vitro and in vivo potency. This review covers the recent advances of isatin derivatives including isatin-azole, isatin-quinoline/quinolone, isatin-furan/coumarin, isatin-hydrazone/(thio)semicarbazone, isatin dimers and isatin-indole hybrids as potential anti-bacterial agents. The enriched structure-activity relationship may pave the way for further rational development of isatin derivatives with broader spectrum, higher potency, lower toxicity and multiple mechanisms of action.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-Bacterial; Hybrid compounds; Isatin; Structure-activity relationship

Mesh:

Substances:

Year:  2018        PMID: 30654239     DOI: 10.1016/j.ejmech.2018.12.017

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

Review 1.  Exploration of the Detailed Structure-Activity Relationships of Isatin and Their Isomers As Monoamine Oxidase Inhibitors.

Authors:  Sunil Kumar; Aathira Sujathan Nair; Mohamed A Abdelgawad; Bijo Mathew
Journal:  ACS Omega       Date:  2022-05-05

Review 2.  Isatin derivatives as broad-spectrum antiviral agents: the current landscape.

Authors:  Tilal Elsaman; Malik Suliman Mohamed; Eyman Mohamed Eltayib; Hatem A Abdel-Aziz; Abualgasim Elgaili Abdalla; Muhammad Usman Munir; Magdi Awadalla Mohamed
Journal:  Med Chem Res       Date:  2022-01-13       Impact factor: 2.351

3.  Rational structural modification of the isatin scaffold to develop new and potent antimicrobial agents targeting bacterial peptidoglycan glycosyltransferase.

Authors:  Yong Wang; Zhiguang Liang; Yuanyuan Zheng; Alan Siu-Lun Leung; Siu-Cheong Yan; Pui-Kin So; Yun-Chung Leung; Wing-Leung Wong; Kwok-Yin Wong
Journal:  RSC Adv       Date:  2021-05-19       Impact factor: 4.036

4.  Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors.

Authors:  Przemysław Czeleń; Agnieszka Skotnicka; Beata Szefler
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

5.  Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.

Authors:  Wagdy M Eldehna; Rofaida Salem; Zainab M Elsayed; Tarfah Al-Warhi; Hamada R Knany; Rezk R Ayyad; Thamer Bin Traiki; Maha-Hamadien Abdulla; Rehan Ahmad; Hatem A Abdel-Aziz; Radwan El-Haggar
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 6.  The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020.

Authors:  Yuzhi Liu; Chengyuan Liang; Liang Xin; Xiaodong Ren; Lei Tian; Xingke Ju; Han Li; Yongbo Wang; Qianqian Zhao; Hong Liu; Wenqiang Cao; Xiaolin Xie; Dezhu Zhang; Yu Wang; Yanlin Jian
Journal:  Eur J Med Chem       Date:  2020-08-06       Impact factor: 6.514

7.  A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor.

Authors:  Huda S Al-Salem; Md Arifuzzaman; Hamad M Alkahtani; Ashraf N Abdalla; Iman S Issa; Aljawharah Alqathama; Fatemah S Albalawi; A F M Motiur Rahman
Journal:  Molecules       Date:  2020-09-25       Impact factor: 4.411

Review 8.  Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.

Authors:  Rameshwar S Cheke; Vaishali M Patil; Sandip D Firke; Jaya P Ambhore; Iqrar A Ansari; Harun M Patel; Sachin D Shinde; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan; Mohd Adnan; Adel Kadri; Mejdi Snoussi
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.